Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04647240 · ClinicalTrials.gov registry record · Phase 2

Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers

A Phase 2 study of Venous Leg Ulcer and Venous Stasis Ulcer, sponsored by Merakris Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
9
Study locations

NCT04647240: Recruiting Phase 2 study of Venous Leg Ulcer and Venous Stasis Ulcer, sponsored by Merakris Therapeutics.

NCT04647240 is a Phase 2 study of Venous Leg Ulcer and Venous Stasis Ulcer that is actively recruiting participants, run by Merakris Therapeutics. The registered enrollment target is 50 participants, below the 244-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04647240, a Phase 2 study of Venous Leg Ulcer and Venous Stasis Ulcer, is actively recruiting participants, sponsored by Merakris Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
9
Study locations

Study Summary

DL-VSU-201 is a randomized, double-blind, placebo controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of Dermacyte® Liquid (MTX-001).

Primary Outcome

Evaluated via patient and/or Investigator reported adverse events that occur during the study

Interventions

  • BIOLOGICAL Dermacyte® Liquid (human amniotic fluid)

Study Locations (9)

California

  • Center for Clinical Research, Inc. - Castro Valley
  • Limb Preservation Platform, Inc. - Fresno
  • Center for Clinical Research Inc. - San Francisco
  • Center for Clinical Research, Inc. - San Francisco

Arizona

  • Compass Medical Research Center - Tucson

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Northwell Health, Inc. - New Hyde Park

Ohio

  • Brock Liden DPM - Circleville

Virginia

  • Salem Vamc - Salem

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-02-26
Est. Completion 2025-10-15
Phase Phase 2
Merakris Therapeutics

1 total trials

What NCT04647240 shows while recruiting

NCT04647240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 244-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Venous Leg Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Dermacyte® Liquid (human amniotic fluid) is the first listed.

NCT04647240 lists 9 locations in 6 states (California, Arizona, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT04647240 about?

NCT04647240 is a clinical study titled "Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers". DL-VSU-201 is a randomized, double-blind, placebo controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of Dermacyte® Liquid (M...

What is the current status of trial NCT04647240?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-02-26. Estimated completion is 2025-10-15.

What conditions does trial NCT04647240 study?

This clinical trial studies the following conditions: Venous Leg Ulcer, Venous Stasis Ulcer.

What interventions are being tested in trial NCT04647240?

The interventions under investigation include: Dermacyte® Liquid (human amniotic fluid) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04647240?

This trial is sponsored by Merakris Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04647240 being conducted?

This trial has 9 study locations across Arizona, California, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04647240's enrollment target sits among peer trials

50 30th of 35 higher than 5 of 35 other Venous Leg Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04647240, the US trial registry maintained by the National Library of Medicine. NCT04647240 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.